Literature DB >> 19374582

Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus.

Christoph K Naber1, Larry M Baddour, Evangelos J Giamarellos-Bourboulis, Ian M Gould, Mathias Herrmann, Bruno Hoen, Adolf W Karchmer, Yoshio Kobayashi, Roman S Kozlov, Daniel Lew, José M Miró, Robert C Moellering, Philippe Moreillon, Georg Peters, Ethan Rubinstein, Harald Seifert, G Ralph Corey.   

Abstract

The increased incidence over the past decade of bloodstream infections (BSIs) caused by gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus, highlights the critical need for a consistent approach to therapy. However, there is currently no international consensus on the diagnosis and management of gram-positive BSIs. The Clinical Consensus Conference on Gram-Positive Bloodstream Infections was convened as a session at the 9th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections held in 2007. Participants discussed various aspects of the practical treatment of patients who present with gram-positive BSI, including therapeutic options for patients with BSIs of undefined origin, the selection of appropriate empirical therapy, and treatment of complicated and uncomplicated BSIs. The opinions of participants about these key issues are reflected in this article.

Entities:  

Mesh:

Year:  2009        PMID: 19374582     DOI: 10.1086/598185

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.

Authors:  Yong Pil Chong; Song Mi Moon; Kyung-Mi Bang; Hyun Jung Park; So-Youn Park; Mi-Na Kim; Ki-Ho Park; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

Review 2.  Once-Daily Treatments for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Are They Good Enough?

Authors:  Sylvain A Lother; Natasha Press
Journal:  Curr Infect Dis Rep       Date:  2017-09-23       Impact factor: 3.725

3.  Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.

Authors:  Ilan Youngster; Erica S Shenoy; David C Hooper; Sandra B Nelson
Journal:  Clin Infect Dis       Date:  2014-04-29       Impact factor: 9.079

4.  Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography.

Authors:  Rasmus V Rasmussen; Ulla Høst; Magnus Arpi; Christian Hassager; Helle K Johansen; Eva Korup; Henrik C Schønheyder; Jens Berning; Sabine Gill; Flemming S Rosenvinge; Vance G Fowler; Jacob E Møller; Robert L Skov; Carsten T Larsen; Thomas F Hansen; Shan Mard; Jesper Smit; Paal S Andersen; Niels E Bruun
Journal:  Eur J Echocardiogr       Date:  2011-06

Review 5.  Predictors of mortality in Staphylococcus aureus Bacteremia.

Authors:  Sebastian J van Hal; Slade O Jensen; Vikram L Vaska; Björn A Espedido; David L Paterson; Iain B Gosbell
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

6.  Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.

Authors:  S Pollett; S M Baxi; G W Rutherford; S B Doernberg; P Bacchetti; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

7.  The management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation.

Authors:  Guy E Thwaites
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

8.  The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia.

Authors:  H G Ternavasio-de la Vega; F Castaño-Romero; S Ragozzino; R Sánchez González; M P Vaquero-Herrero; M Siller-Ruiz; G Spalter-Glicberg; C Ramírez-Baum; S Rodríguez-Rodríguez; J E García-Sánchez; I García-García; M Marcos
Journal:  Epidemiol Infect       Date:  2018-09-03       Impact factor: 4.434

9.  Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.

Authors:  Guy Thwaites; Cressida Auckland; Gavin Barlow; Richard Cunningham; Gerry Davies; Jonathan Edgeworth; Julia Greig; Susan Hopkins; Dakshika Jeyaratnam; Neil Jenkins; Martin Llewelyn; Sarah Meisner; Emmanuel Nsutebu; Tim Planche; Robert C Read; Matthew Scarborough; Marta Soares; Robert Tilley; M Estée Török; John Williams; Peter Wilson; Sarah Wyllie; A Sarah Walker
Journal:  Trials       Date:  2012-12-18       Impact factor: 2.279

Review 10.  The complex pathogenesis of bacteremia: from antimicrobial clearance mechanisms to the genetic background of the host.

Authors:  Eirini Christaki; Evangelos J Giamarellos-Bourboulis
Journal:  Virulence       Date:  2013-09-25       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.